About the Study:
Cytomegalovirus (CMV) is a common virus for people of all ages. According to the CDC, in the United States, it is estimated that nearly 1 in 3 children are already infected with CMV by the age of 5. It is also estimated that over half of adults have been infected with CMV by the time they are 40 years old. Once CMV is in the body, it stays there for life and can reactivate. While most people with CMV infection have no symptoms are unaware of infection some may experience symptoms such as fever, sore throat, fatigue, swollen glands, and CMV occasionally can cause mononucleosis or hepatitis. CMV is passed in body fluids such as saliva, blood, urine, tears, semen, and breast milk. CMV is typically passed through direct contact with saliva or urine, especially in babies and children, sexual contact, and from breast milk to nursing infants. Those with weakened immune systems can be even more affected by CMV experiencing symptoms that affect the eyes, liver. Lugs, esophagus, stomach, and intestines. CMV is the most common infectious cause of birth defects in the US. Babies born with CMV can have brain, liver, spleen, lung, and growth problems.
There is currently no vaccine to prevent CMV.
Rochester Clinical Research is seeking volunteers to participate in a study evaluating the safety and effectiveness of a vaccine to prevent CMV. This study will last approximately 4 years with 14 visits to our office and 18 telephone calls.
Study-related care is available to participants at no cost and health insurance is not required nor needed. Compensation for time and travel is available to those who qualify.
To qualify for this study, you must be between the ages of 16-40, been assigned female gender at birth, and have exposure to at least 1 child under age 5 for at least 8 hours per week.
- Be between the ages 16-40 and assigned female gender at birth
- Have exposure to at least 1 child under age 5 for at least 8 hours per week
- Be in stable health
- Please note, other conditions apply***